KTTA (Pasithea Therapeutics Corp.) Enterprise Value-to-Revenue Coefficient

The lack of stable income and risks associated with psychiatric research are weighing on shares, and consequently, the EV-to-revenue ratio on GURU.Markets reflects current volatility, with the value holding at 0.00. The prospects for Pasithea Therapeutics (KTTA) rely on the success of macrophage inhibitors and M&A potential, while updated management strictly controls operating expenses to preserve liquidity.
Pasithea Therapeutics - analytical breakdowns and key metrics (KTTA)

The balance between developing ketamine therapy clinics and creating neurofibromatosis drugs allows Pasithea Therapeutics (KTTA) to diversify its cash flows. By analyzing the enterprise value-to-sales multiple, an investor assesses the market value of the business, including debt, relative to revenue, where a sharp increase in the indicator signals inflated growth expectations and the risk of overpayment, calling into question the sustainability of the invested capital.